

### 3rd Malaysia - Japan Symposium on Pharmaceutical Regulatory System

DATE: 31<sup>st</sup> July 2025

Time	Item
8:30 - 9:00	<b>Networking Session</b>
9:00 - 9:10 (10 min)	<b>Opening Remarks / Keynote</b> <ul style="list-style-type: none"> <li>• <b>Dr. Azuana Ramli</b>, Deputy Director General of Health (Pharmaceutical Services) (5min)</li> <li>• <b>Dr. Kondo Emiko</b>, Senior Executive Director, PMDA (5 min)</li> </ul>
9:10 - 10:20 (70 min)	<b>Regulatory Review &amp; Updates</b> <ul style="list-style-type: none"> <li>• <b>Mdm. Rosliza Lajis</b>, Deputy Director of NPRA (20 min)</li> <li>• <b>Mr. OKUBO Takayuki</b>, Director, Office of International Regulatory Affairs, MHLW (20 min)</li> <li>• Q&amp;A (30 min)</li> </ul>
10:20 - 10:30	<b>Photo Session, 10 min</b>
10:30 – 10:50	<b>BREAK, 20 min</b>
10:50 - 12:00 (70 min)	<b>Session 1: Real World Data</b>  <u>Chair</u> <b>Ms. ENDO Ayumi</b> , Office of Asia Training Center and International Cooperation (OAIC)  <u>Topic &amp; Speaker</u> <ol style="list-style-type: none"> <li>1. <i>Real-World Evidence for Pre-Market Approval : Malaysian Perspective</i> (20min)  <b>Ms. Hu Suk Kwan</b>, New Drug Product Section, NPRA</li> <li>2. <i>Utilization of Real World Data in Applications for Approval and its Expectations in Japan</i> (20min)  <b>Ms. Matsuzaki Yu</b>, Office of Non-Clinical and Clinical Compliance I, PMDA</li> </ol>

	<p>Panel discussion and Q&amp;A (30 min)</p> <p><u>Panelists</u></p> <ol style="list-style-type: none"> <li>1. Ms. Hu Suk Kwan, New Drug Product Section, NPRA</li> <li>2. Ms. Matsuzaki Yu, Office of Non-Clinical and Clinical Compliance I, PMDA</li> <li>3. Ms. Soo Li Ping, Head of Regulatory Affairs, AstraZeneca Malaysia (PhAMA)</li> <li>4. Mr. Takayuki Imaeda, Vice Chairperson, Drug Evaluation Committee, JPMA</li> </ol>
12:00 - 13:10 (70 min)	<p><b>Session 2: Risk Management Plan (RMP)</b></p> <p><u>Chair</u> <b>Dr. Kitahara Jun</b>, Head of PMDA Asia Office</p> <p><u>Topic &amp; Speaker</u></p> <ol style="list-style-type: none"> <li>1. <i>Post-registration Risk Management Plan: An insight into the Malaysia-Specific Annex (MSA)</i> (20min) <b>Dr. Vidhya Hariraj</b>, Pharmacovigilance Section, NPRA</li> <li>2. <i>Overview of Japanese Risk Management Plan</i> (20min) <b>Ms. Kobayashi Ayano</b>, Office of Pharmacovigilance II, PMDA</li> </ol> <p>Panel discussion and Q&amp;A (30 min)</p> <p><u>Panelists</u></p> <ol style="list-style-type: none"> <li>1. Dr. Vidhya Hariraj, Pharmacovigilance Section, NPRA</li> <li>2. Ms. Kobayashi Ayano, Office of Pharmacovigilance II, PMDA</li> <li>3. Dr. Evelyn Loh Yun Xi, Biologics Section, NPRA</li> <li>4. Dr. Maeda Daisuke, Director Office of Pharmacovigilance II, PMDA</li> <li>5. Dr. Matsumoto Jun, Coordination Director, Office of Asia Training Center and International Cooperation (OAIC)</li> </ol>
13:10 - 14:10	<b>Lunch, 60 min</b>
14:10 - 15:20 (70 min)	<p><b>Session 3: Facilitated Registration Pathway</b></p> <p><u>Chair</u></p>

	<p><b>Mdm. Rosliza Lajis,</b> Deputy Director Centre of Product &amp; Cosmetic Evaluation, NPRA</p> <p><u>Topic &amp; Speaker</u></p> <p>1. <i>Advancing Regulatory Efficiency: Updates on Malaysia's FRP Implementation</i> (20min) <b>Dr. Noraisyah Mohd Sani,</b> Head of New Drug Product Section, NPRA</p> <p>2. <i>Utilization of Japanese review report for Malaysia's Facilitated Registration</i> (20min) <b>Mr. Shimizu Kaito,</b> Office of International Programs, PMDA</p> <p>Panel discussion and Q&amp;A (30 min)</p> <p><u>Panelists</u></p> <ol style="list-style-type: none"> <li>1. Dr. Noraisyah Mohd Sani, Head of New Drug Product Section, NPRA</li> <li>2. Mr. Shimizu Kaito, Office of International Programs, PMDA</li> <li>3. Ms. Long Siew Mei, Regulatory Affairs Director, Merck Sharp &amp; Dohme Malaysia (PhAMA)</li> <li>4. Ms. Ayaha Watanabe, Singapore &amp; Malaysia Group Leader, Asian Division, International Affairs Committee, JPMA</li> </ol>
15:20 - 15:40	<b>(BREAK, 20 min)</b>
15:40 - 16:50 (70 min)	<p><b>Session 4: Clinical Trial</b></p> <p><u>Chair</u></p> <ol style="list-style-type: none"> <li>1. <b>Dr. Khairulanwar Burhanuddin</b> Head of BE Centre &amp; Ethics Committee Section, NPRA</li> <li>2. <b>Dr. Kitahara Jun</b> Head of PMDA Asia Office</li> </ol> <p><u>Topic &amp; Speaker</u></p> <p>1. <i>From policy to practice : Implementing Clinical Trial Regulations in Malaysia (NPRA)</i> (20min) <b>Dr. Zaril Harza Zakaria,</b> Head of Investigational Product Evaluation and Safety Section, NPRA</p>

	<p>2. <i>Shaping Asia's Clinical Trial Landscape – Insights from the ATLAS Initiative and its Regulatory Collaborations</i> (20min)</p> <p><b>Dr. Mitsumi Terada</b>, Section Head, Asian Partnerships Section, Department of International Clinical Development/ National Cancer Centre Hospital, Japan</p> <p>Panel discussion and Q&amp;A (30 min)</p> <p><u>Panelists</u></p> <ol style="list-style-type: none"> <li>3. Dr. Zaril Harza Zakaria, Head of Investigational Product Evaluation and Safety Section, NPRA</li> <li>4. Dr. Mitsumi Terada, Section Head, Asian Partnerships Section, Department of International Clinical Development/ National Cancer Centre Hospital, Japan</li> <li>5. Dr. Akhmal Yusof, CEO of Clinical Research Malaysia (CRM)</li> <li>6. Dr. Kitahara Jun, Head of PMDA Asia Office</li> </ol>
16:50 - 17:00 (10 min)	<p><b>Closing Remarks</b></p> <ul style="list-style-type: none"> <li>• <b>Mr. OKUBO Takayuki</b>, Director, Office of International Regulatory Affairs, MHLW (5 min)</li> <li>• <b>Mdm. Rosliza Lajis</b>, Deputy Director of NPRA (5min)</li> </ul>

As of 23<sup>rd</sup> July 2025